Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Specialty — Goodwill

Other segment segments

Affordable Medicines
$158.02M
AvKARE
$69.47M0.0%

Similar metrics at other companies

PFG
PFGCSpecialty — Goodwill
$133.4M0.0%
Sunbelt Rentals Holdings logo
SUNBSpecialty — Goodwill
$1.11B+6.6%
B&G Foods logo
BGSSpecialty — Goodwill
$219.25M-2.0%
CNA Financial logo
CNASpecialty — Goodwill
$117M0.0%
Radian Group logo
RDNSpecialty — Goodwill
$5M
GTL
GTLSSpecialty Products — Goodwill
$583.5M+2.1%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemAffordable MedicinesSpecialtyAv KARETotal
Balance as of December 31, 2024$161,659$366,312$69,465$597,436
Currency translation(1,966)(1,966)
Balance as of December 31, 2025159,693366,31269,465595,470
Currency translation(1,971)(1,971)
Balance as of June 30, 2026$157,722$366,312$69,465$593,499

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — goodwill?
Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — goodwill of $366.31M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — goodwill changed year-over-year?
Amneal Pharmaceuticals, Inc.'s specialty — goodwill decreased by 0.0% year-over-year, from $366.31M to $366.31M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — goodwill?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — goodwill has grown at a 7.6% compound annual growth rate (CAGR), from $1.09B to $1.47B.
What does specialty — goodwill mean?
Represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations specifically allocated to the specialty pharmaceutical segment. This intangible asset reflects the premium paid for brand equity, market position, and future growth potential within the specialty medicine portfolio.

Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude